KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Acadia Pharmaceuticals (ACAD) Short term Debt: 2009-2012

Historic Short term Debt for Acadia Pharmaceuticals (ACAD) over the last 3 years, with Mar 2012 value amounting to $22,000.

  • Acadia Pharmaceuticals' Short term Debt fell 50.00% to $22,000 in Q1 2012 from the same period last year, while for Mar 2012 it was $22,000, marking a year-over-year decrease of 50.00%. This contributed to the annual value of $32,000 for FY2011, which is 58.97% down from last year.
  • According to the latest figures from Q1 2012, Acadia Pharmaceuticals' Short term Debt is $22,000, which was down 31.25% from $32,000 recorded in Q4 2011.
  • In the past 5 years, Acadia Pharmaceuticals' Short term Debt ranged from a high of $685,000 in Q1 2009 and a low of $22,000 during Q1 2012.
  • Over the past 3 years, Acadia Pharmaceuticals' median Short term Debt value was $44,000 (recorded in 2011), while the average stood at $90,667.
  • Data for Acadia Pharmaceuticals' Short term Debt shows a maximum YoY slumped of 84.88% (in 2011) over the last 5 years.
  • Quarterly analysis of 4 years shows Acadia Pharmaceuticals' Short term Debt stood at $365,000 in 2009, then crashed by 78.63% to $78,000 in 2010, then slumped by 58.97% to $32,000 in 2011, then tumbled by 50.00% to $22,000 in 2012.
  • Its Short term Debt stands at $22,000 for Q1 2012, versus $32,000 for Q4 2011 and $37,000 for Q3 2011.